Skip to search formSkip to main contentSkip to account menu

Anti-CD20-engineered Toxin Body MT-3724

Known as: MT-3724 
An engineered toxin body (ETB) composed of the single-chain variable fragment (ScFv) from an antibody targeting CD20 that is linked to a modified… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.
TPS8074Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit… 
Review
2019
Review
2019
A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin Lymphoma (NHL… 
2019
2019
Abstract 2060: Combination of CD20 targeted engineered toxin body, MT-3724, with chemotherapy or IMiDs for the treatment of non Hodgkin's lymphoma
MT-3724 is a novel recombinant fusion protein consisting of a CD20 binding variable fragment (scFv) fused to Shiga-like toxin-I… 
2019
2019
Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Background: The near ubiquity and persistence of CD20 expression in B-cell malignancies provides a strong rationale for novel… 
2019
2019
A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and…
Introduction: Approximately 40% of all newly diagnosed Diffuse large B-cell lymphoma (DLBCL) patients are either refractory or… 
2018
2018
Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
7580Background: MT-3724 is a novel recombinant fusion protein consisting of a CD20 binding variable fragment (scFv) fused to… 
2017
2017
Abstract 3651: Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma
Mantle cell lymphoma (MCL) accounts for 6-8% of all non-Hodgkin lymphoma cases and is a therapeutic challenge. MCL is… 
2016
2016
Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)
Background Novel mechanisms of action (MOA) are needed for the treatment of NHL. Because of the ubiquity and persistence of CD20… 
2016
2016
Abstract CT049: Phase I/Ib study of the novel CD20-targeted immunotoxin MT-3724 in relapsed/refractory non-Hodgkin's B-cell lymphoma
Background Anti-CD20 monoclonal antibody (MAb) therapy is widely employed in the treatment of non-Hodgkin9s B-cell lymphoma (NHL… 
2014
2014
Abstract 647: CD20-specific Engineered Toxin Body demonstrates direct cell kill of multiple B-cell Non-Hodgkin's lymphoma types
The B-cell membrane protein CD20 is expressed by both benign and neoplastic lymphocytes. It has been a superb target for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)